Analyst Research Report Snapshot

Title:

TOPOTARGET - FDA ACCEPTS FILING OF BELEODAQ

Price:

$10.00

Provider:

Edison Investment Research

Date:

10 Feb 2014

Pages:

3

Type:

AcrobatPDF

Companies referenced:

TOPO.CO

Available for Immediate Download
Summary:

Topotarget’s belinostat, now with the brand name Beleodaq, could be approved on 9 August 2014 (PDUFA date). The FDA has accepted the product filing and granted priority review. Topotarget will receive milestone payments worth c $17.8m from its partner Spectrum, and could receive a further $25m for product approval. We continue to be confident that belinostat will be approved, due to data from the BELIEF trial. In the meantime, Topotarget should disclose its broader development plans for belinostat in H114. We increase our valuation to DKK1,434m.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.